An integrated population pharmacokinetic model of rivaroxaban in 4,918 patients showed that creatinine clearance had a modest influence on exposure, whereas age and BMI had a minor influence.
How do patient factors such as renal function, age, and weight affect the population pharmacokinetics of rivaroxaban?
An integrated population pharmacokinetic model demonstrates that creatinine clearance modestly influences rivaroxaban exposure, while age and BMI have minor effects, enabling exposure prediction in special patient subgroups.
The population pharmacokinetics (PK) of rivaroxaban have been evaluated in several population-specific models. We developed an integrated population PK model using pooled data from 4,918 patients in 7 clinical trials across all approved indications. Effects of gender, age, and weight on apparent clearance (CL/F) and apparent volume of distribution (V/F), renal function, and comedication on CL/F, and relative bioavailability as a function of dose (F) were analyzed. Virtual subpopulations for exposure simulations were defined by age, creatinine clearance (CrCL) and body mass index (BMI). Rivaroxaban PK were adequately described by a one-compartment disposition model with a first-order absorption rate constant. Significant effects of CrCL, use of comedications, and study population on CL/F, age, weight, and gender on V/F, and dose on F were identified. CrCL had a modest influence on exposure, whereas age and BMI had a minor influence. The model was suitable to predict rivaroxaban exposure in patient subgroups of special interest.
Willmann et al. (Mon,) conducted a other in All approved indications for rivaroxaban (n=4,918). Rivaroxaban was evaluated on Population pharmacokinetics (apparent clearance, apparent volume of distribution, relative bioavailability). An integrated population pharmacokinetic model of rivaroxaban in 4,918 patients showed that creatinine clearance had a modest influence on exposure, whereas age and BMI had a minor influence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: